Feasibility of intravenous administration of landiolol hydrochloride for multislice computed tomography coronary angiography: initial experience.
BACKGROUND
The feasibility of using landiolol hydrochloride in multislice computed tomography (MSCT) coronary angiography (CAG) was investigated in the present study.


RESULTS
Landiolol hydrochloride was continuously administered intravenously to 145 patients before starting MSCT CAG. Hemodynamic changes [blood pressure (BP), heart rate (HR)], adverse effects, image quality using a 5-point scale, and accuracy of detecting significant stenoses (>or=50% reduction in lumen diameter) were evaluated. HR was significantly reduced during injection, and quickly recovered after cessation of administration, of landiolol hydrochloride. Neither significant changes in BP nor adverse effects occurred. Among visible segments, 1,869 (94%) displayed an excellent (83%) or good (11%) image quality. Diagnostic accuracy was evaluated in 39 of 145 patients who underwent invasive CAG within 3 weeks after MSCT. The sensitivity, specificity, positive predictive value, and negative predictive value of MSCT CAG for detection of significant stenoses in assessable segments were excellent (per artery: 94%, 98%, 92%, and 100%; per segment: 92%, 98%, 94%, and 96%, respectively).


CONCLUSIONS
Intravenous administration of landiolol hydrochloride reduces HR without a significant reduction in BP, which enables favorable image quality and diagnostic accuracy without adverse effects, making this agent feasible as a premedication for MSCT CAG.
Isobe
Satoshi
S
Department of Cardiology, Kami-iida Daiichi General Hospital, Kita-machi, Kita-ku, Nagoya, Japan. sisobe@med.nagoya-u.ac.jp
Sato
Kimihide
K
Sugiura
Kaichiro
K
Mimura
Takeo
T
Kobayashi
Mikiko
M
Meno
Chizuka
C
Kato
Makoto
M
Ishii
Hideki
H
Murohara
Toyoaki
T
D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging* / Q000503:physiopathology; D023921:Coronary Stenosis / Q000000981:diagnostic imaging* / Q000503:physiopathology; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000494:pharmacology*; D014057:Tomography, X-Ray Computed; D014508:Urea / Q000031:analogs & derivatives* / Q000494:pharmacology
D000889:Anti-Arrhythmia Agents; D009025:Morpholines; C077049:landiolol; D014508:Urea